← All trials
NCT04274049
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 18, 2019
- Primary completion
- Jul 16, 2021
- Completion date
- Mar 6, 2022
- First posted
- Feb 18, 2020
- Last posted
- Feb 18, 2020
- Enrollment
- 240
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Beijing Northland Biotech. Co., Ltd.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.